Who We Are

Bayshore Growth Partners is an independent financial advisory and investment firm focused exclusively on healthcare services. Bayshore Growth Partners provides principal-level attention to every opportunity, developing a deep understanding of each company’s growth drivers and operational levers to ensure the best path forward.

What We Do

Bayshore Growth Partners provides financial advisory services and capital to middle market healthcare services companies to help unlock value and maximize results.

Sector Focus


Steven Carmen

Managing Partner

Steve Carmen is the Managing Partner of Bayshore Growth Partners, an independent financial advisory and investment firm focused exclusively on healthcare services. Steve has 15+ years of experience in corporate transactions and business development strategy as an advisor, investor and operator. Prior to forming Bayshore Growth Partners, Steve was a Vice President with PwC Corporate Finance, where he provided mergers & acquisitions advisory services to clients in the healthcare services sector. Prior to PwC, Steve led the corporate development efforts for two privately-held middle market companies, focusing on mergers & acquisitions and business development strategy. Steve helped drive revenue growth and profit margin expansion, which ultimately led to successful liquidity events. Prior to his corporate development experience, Steve worked in investment banking, focusing on mergers & acquisitions, private capital, and capital markets client coverage.

Steve holds an MBA from Kellogg School of Management at Northwestern University, and a BS in Business from Florida State University. Steve holds his FINRA Series 7, 63, and 79 licenses.


Andrew Adams

Managing Director

Andrew has 15+ years of experience in mergers & acquisitions, strategy, and operations. Prior to joining Bayshore Growth Partners, Andrew was Chief Financial Officer for a private equity backed company. Prior to this role, Andrew was an Investment Partner at a family office, where he co-led multiple investments across various industries. Prior to this role, Andrew was a consultant with Bain & Company, where he advised Fortune 100 healthcare companies on M&A, strategy, and operations. Prior to his consulting experience, Andrew was an investment professional at Lake Capital and an investment banking analyst with J.P. Morgan. In addition to his previous roles, Andrew has held multiple advisory roles in healthcare organizations, including as Advisory Panel Member for Improving Healthcare Systems of PCORI and as an advisor to Locemia, creators of the nasal glucagon Baqsimi (sold to Eli Lilly).

Andrew holds an MBA in Health Care Management from The Wharton School and a BBA in Finance from the University of Michigan. Andrew holds his FINRA Series 79 license.


Daniel Shaw

Managing Director

Daniel Shaw is a Managing Director at Bayshore Growth Partners. Daniel has more than a decade of transaction and accounting experience. Prior to joining Bayshore Growth Partners, Daniel worked as a Director at Alvarez and Marsal, where he provided sell-side and buy-side financial due diligence for private equity clients, with specific focus on healthcare transactions. Prior to Alvarez and Marsal, Daniel worked at KPMG, where he gained a strong understanding of accounting principles with an initial focus on audit, before transitioning to advisory and transaction services.

Daniel holds a Bachelor of Science in Accounting from Louisiana Tech University and is a licensed CPA in the State of Tennessee. Daniel holds his FINRA Series 79 license.


Alex Dean

Vice President

Alex Dean is a Vice President at Bayshore Growth Partners. Prior to joining Bayshore Growth Partners, Alex worked in Strategy & Operations at DaVita, one of the largest kidney care providers in the US. Prior to attending business school, Alex served in the U.S. Marine Corps for 8 years as an infantry officer and as a marine advisor. Alex has work experience in Asia, Europe, and South America.

Alex holds an MBA from the University of Virginia Darden School of Business, and a BA in Political Science from Seton Hall University. Alex holds his FINRA Series 79 license.